<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33255513</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>23</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Peripheral Glycolysis in Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8924</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21238924</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous system and peripheral cells. Glycolysis is the conversion of glucose to pyruvate or lactate which results in the generation of ATP and has been shown to be abnormal in peripheral cells in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. Changes to the glycolytic pathway are seen early in neurodegenerative disease and highlight how in multiple neurodegenerative conditions pathology is not always confined to the nervous system. In this paper, we review the abnormalities described in glycolysis in the three most common neurodegenerative diseases. We show that in all three diseases glycolytic changes are seen in fibroblasts, and red blood cells, and that liver, kidney, muscle and white blood cells have abnormal glycolysis in certain diseases. We highlight there is potential for peripheral glycolysis to be developed into multiple types of disease biomarker, but large-scale bio sampling and deciphering how glycolysis is inherently altered in neurodegenerative disease in multiple patients' needs to be accomplished first to meet this aim.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Simon M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-2781-6478</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0003-4418-7375</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortiboys</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>na</GrantID><Agency>Neuroscience Research Institute Foundation</Agency><Country/></Grant><Grant><GrantID>ARUK-PCRF2016A-1</GrantID><Agency>Alzheimer's Research UK</Agency><Country/></Grant><Grant><GrantID>F-1301</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NA</GrantID><Agency>NIHR Sheffield Biomedical Research Center</Agency><Country/></Grant><Grant><GrantID>216340/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>F1301</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">fibroblasts</Keyword><Keyword MajorTopicYN="N">glycolysis</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">muscle</Keyword><Keyword MajorTopicYN="N">red blood cells</Keyword></KeywordList><CoiStatement>The authors have no financial or personal relationships with other people/organizations that could inappropriately influence (bias) their work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33255513</ArticleId><ArticleId IdType="pmc">PMC7727792</ArticleId><ArticleId IdType="doi">10.3390/ijms21238924</ArticleId><ArticleId IdType="pii">ijms21238924</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2016 Neurology Collaborators Global, regional, and national burden of neurological disorders, 1990&#x2013;2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459&#x2013;480. doi: 10.1016/S1474-4422(18)30499-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A. Defining neurodegenerative diseases. BMJ. 2002;324:1465&#x2013;1466. doi: 10.1136/bmj.324.7352.1465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.324.7352.1465</ArticleId><ArticleId IdType="pmc">PMC1123425</ArticleId><ArticleId IdType="pubmed">12077015</ArticleId></ArticleIdList></Reference><Reference><Citation>Procaccini C., Santopaolo M., Faicchia D., Colamatteo A., Formisano L., De Candia P., Galgani M., De Rosa V., Matarese G. Role of metabolism in neurodegenerative disorders. Metabolism. 2016;65:1376&#x2013;1390. doi: 10.1016/j.metabol.2016.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2016.05.018</ArticleId><ArticleId IdType="pubmed">27506744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hames B.D., Hooper N.M. In: Instant Notes in Biochemistry. Kingston F., editor. Taylor &amp; Francis Ltd.; Abingdon, UK: 2000. pp. 278&#x2013;288.</Citation></Reference><Reference><Citation>Allen S.P., Hall B., Castelli L.M., Francis L., Woof R., Siskos A.P., Kouloura E., Gray E., Thompson A.G., Talbot K., et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain. 2019;142:586&#x2013;605. doi: 10.1093/brain/awy353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy353</ArticleId><ArticleId IdType="pmc">PMC6391613</ArticleId><ArticleId IdType="pubmed">30698736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell S.M., De Marco M., Barnes K., Shaw P.J., Ferraiuolo L., Blackburn D.J., Mortiboys H., Venneri A. Deficits in Mitochondrial Spare Respiratory Capacity Contribute to the Neuropsychological Changes of Alzheimer&#x2019;s Disease. J. Pers. Med. 2020;10:32. doi: 10.3390/jpm10020032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10020032</ArticleId><ArticleId IdType="pmc">PMC7354560</ArticleId><ArticleId IdType="pubmed">32365522</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C., Kawamata H., Bredvik K., Arreguin A., Cajamarca S.A., Hupf J.C., Ravits J., Miller T.M., Maragakis N.J., Hales C.M., et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol. Neurodegener. 2017;12:76. doi: 10.1186/s13024-017-0217-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0217-5</ArticleId><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag K.-C., Ryu W.-I., Amirault K.M., Healy R.A., Siegel A.J., McPhie N.L., Forester B., Cohen B.M. Late-onset Alzheimer&#x2019;s disease is associated with inherent changes in bioenergetics profiles. Sci. Rep. 2017;7:14038. doi: 10.1038/s41598-017-14420-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14420-x</ArticleId><ArticleId IdType="pmc">PMC5656579</ArticleId><ArticleId IdType="pubmed">29070876</ArticleId></ArticleIdList></Reference><Reference><Citation>Dashty M. A quick look at biochemistry: Carbohydrate metabolism. Clin. Biochem. 2013;46:1339&#x2013;1352. doi: 10.1016/j.clinbiochem.2013.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2013.04.027</ArticleId><ArticleId IdType="pubmed">23680095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipkiss A.R. Aging, Alzheimer&#x2019;s Disease and Dysfunctional Glycolysis; Similar Effects of Too Much and Too Little. Aging Dis. 2019;10:1328&#x2013;1331. doi: 10.14336/AD.2019.0611.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2019.0611</ArticleId><ArticleId IdType="pmc">PMC6844594</ArticleId><ArticleId IdType="pubmed">31788344</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.-B., Gu J.-D., Zhou Q.-H. Review of aerobic glycolysis and its key enzymes&#x2014;New targets for lung cancer therapy. Thorac. Cancer. 2015;6:17&#x2013;24. doi: 10.1111/1759-7714.12148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.12148</ArticleId><ArticleId IdType="pmc">PMC4448463</ArticleId><ArticleId IdType="pubmed">26273330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wamelink M.M., Struys E.A., Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: A review. J. Inherit. Metab. Dis. 2008;31:703&#x2013;717. doi: 10.1007/s10545-008-1015-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10545-008-1015-6</ArticleId><ArticleId IdType="pubmed">18987987</ArticleId></ArticleIdList></Reference><Reference><Citation>Dienel G.A., Cruz N.F. Aerobic glycolysis during brain activation: Adrenergic regulation and influence of norepinephrine on astrocytic metabolism. J. Neurochem. 2016;138:14&#x2013;52. doi: 10.1111/jnc.13630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13630</ArticleId><ArticleId IdType="pubmed">27166428</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L., Tsui W.-H., De Santi S., Li J., Rusinek H., Convit A., Li Y., Boppana M., De Leon M.J. Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis. Neurology. 2005;64:1860&#x2013;1867. doi: 10.1212/01.WNL.0000163856.13524.08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000163856.13524.08</ArticleId><ArticleId IdType="pubmed">15955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.-T., Beiser A., Breteler M.M.B., Fratiglioni L., Helmer C., Hendrie H.C., Honda H., Ikram M.A., Langa K.M., Lobo A., et al. The changing prevalence and incidence of dementia over time&#x2014;Current evidence. Nat. Rev. Neurol. 2017;13:327&#x2013;339. doi: 10.1038/nrneurol.2017.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.63</ArticleId><ArticleId IdType="pubmed">28497805</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M.J. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer&#x2019;s Disease International; London, UK: 2015.</Citation></Reference><Reference><Citation>Alzheimer&#x2019;s Association  What is Dementia.  [(accessed on 7 May 2020)]; Available online:  https://www.alz.org/alzheimers-dementia/what-is-dementia.</Citation></Reference><Reference><Citation>Perl D.P. Neuropathology of Alzheimer&#x2019;s disease. Mt. Sinai J. Med. 2010;77:32&#x2013;42. doi: 10.1002/msj.20157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/msj.20157</ArticleId><ArticleId IdType="pmc">PMC2918894</ArticleId><ArticleId IdType="pubmed">20101720</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko A.G., Vaishnavi S.N., Couture L., Sacco D., Shannon B.J., Mach R.H., Morris J.C., Raichle M.E., Mintun M.A. Spatial correlation between brain aerobic glycolysis and amyloid-&#x3b2; (A&#x3b2;) deposition. Proc. Natl. Acad. Sci. USA. 2010;107:17763&#x2013;17767. doi: 10.1073/pnas.1010461107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010461107</ArticleId><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko A., Gordon B.A., Goyal M.S., Su Y., Blazey T., Durbin T.J., Couture L.E., Christensen J.J., Jafri H., Morris J.C., et al. Aerobic glycolysis and tau deposition in preclinical Alzheimer&#x2019;s disease. Neurobiol. Aging. 2018;67:95&#x2013;98. doi: 10.1016/j.neurobiolaging.2018.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.03.014</ArticleId><ArticleId IdType="pmc">PMC5955846</ArticleId><ArticleId IdType="pubmed">29655050</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus C., Mena E., Subramaniam R.M. Brain PET in the diagnosis of Alzheimer&#x2019;s disease. Clin. Nucl. Med. 2014;39:e413&#x2013;e426. doi: 10.1097/RLU.0000000000000547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0000000000000547</ArticleId><ArticleId IdType="pmc">PMC4332800</ArticleId><ArticleId IdType="pubmed">25199063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigl M., Bleyl A.-D., Zedlick D., Arendt T., Bigl V., Eschrich K. Changes of activity and isozyme pattern of phosphofructokinase in the brains of patients with Alzheimer&#x2019;s disease. J. Neurochem. 1996;67:1164&#x2013;1171. doi: 10.1046/j.1471-4159.1996.67031164.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67031164.x</ArticleId><ArticleId IdType="pubmed">8752123</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigl M., Arendt T., Bigl V., Eschrich K., Br&#xfc;ckner M.K. Activities of key glycolytic enzymes in the brains of patients with Alzheimer&#x2019;s disease. J. Neural Transm. 1999;106:499&#x2013;511. doi: 10.1007/s007020050174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020050174</ArticleId><ArticleId IdType="pubmed">10443553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M., Bogdanovic N., Nakagawa H., Volkmann I., Aoki M., Winblad B., Sakai J., Tjernberg L. Analysis of microdissected neurons by 18O mass spectrometry reveals altered protein expression in Alzheimer&#x2019;s disease. J. Cell. Mol. Med. 2012;16:1686&#x2013;1700. doi: 10.1111/j.1582-4934.2011.01441.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01441.x</ArticleId><ArticleId IdType="pmc">PMC3822682</ArticleId><ArticleId IdType="pubmed">21883897</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson I.A., Chundu K.R., Davies-Hill T., Honer W.G., Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer&#x2019;s disease. Ann. Neurol. 1994;35:546&#x2013;551. doi: 10.1002/ana.410350507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410350507</ArticleId><ArticleId IdType="pubmed">8179300</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y., Varma V.R., Varma S., Casanova R., Dammer E., Pletnikova O., Chia C.W., Egan J.M., Ferrucci L., Troncoso J., et al. Evidence for brain glucose dysregulation in Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:318&#x2013;329. doi: 10.1016/j.jalz.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.011</ArticleId><ArticleId IdType="pmc">PMC5866736</ArticleId><ArticleId IdType="pubmed">29055815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Zhao F., Ma X., Perry G., Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer&#x2019;s disease: Recent advances. Mol. Neurodegener. 2020;15:30. doi: 10.1186/s13024-020-00376-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00376-6</ArticleId><ArticleId IdType="pmc">PMC7257174</ArticleId><ArticleId IdType="pubmed">32471464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell S.M., Barnes K., Clemmens H., Al-Rafiah A.R., Al-Ofi E.A., Leech V., Bandmann O., Shaw P.J., Blackburn D.J., Ferraiuolo L., et al. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer&#x2019;s Disease. J. Mol. Biol. 2018;430:3942&#x2013;3953. doi: 10.1016/j.jmb.2018.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2018.08.019</ArticleId><ArticleId IdType="pmc">PMC6193139</ArticleId><ArticleId IdType="pubmed">30171839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorbi S., Piacentini S., Latorraca S., Piersanti P., Amaducci L. Alterations in metabolic properties in fibroblasts in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1995;9:73&#x2013;77. doi: 10.1097/00002093-199509020-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199509020-00003</ArticleId><ArticleId IdType="pubmed">7662326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims N.R., Finegan J.M., Blass J.P. Altered glucose metabolism in fibroblasts from patients with Alzheimer&#x2019;s disease. N. Engl. J. Med. 1985;313:638&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">4022053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorbi S., Mortilla M., Piacentini S., Tonini S., Amaducci L. Altered hexokinase activity in skin cultured fibroblasts and leukocytes from Alzheimer&#x2019;s disease patients. Neurosci. Lett. 1990;117:165&#x2013;168. doi: 10.1016/0304-3940(90)90138-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(90)90138-Y</ArticleId><ArticleId IdType="pubmed">2149746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims N.R., Blass J.P. Phosphofructokinase activity in fibroblasts from patients with Alzheimer&#x2019;s disease and age- and sex-matched controls. Metab. Brain Dis. 1986;1:83&#x2013;90. doi: 10.1007/BF00998479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00998479</ArticleId><ArticleId IdType="pubmed">2977422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminsky Y.G., Reddy V.P., Ashraf G.M., Ahmad A., Benberin V.V., Kosenko E.A., Aliev G. Age-related defects in erythrocyte 2,3-diphosphoglycerate metabolism in dementia. Aging Dis. 2013;4:244&#x2013;255. doi: 10.14336/AD.2013.0400244.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2013.0400244</ArticleId><ArticleId IdType="pmc">PMC3794721</ArticleId><ArticleId IdType="pubmed">24124630</ArticleId></ArticleIdList></Reference><Reference><Citation>Carelli-Alinovi C., Dinarelli S., Sampaolese B., Misiti F., Girasole M. Morphological changes induced in erythrocyte by amyloid beta peptide and glucose depletion: A combined atomic force microscopy and biochemical study. Biochim. Biophys. Acta Biomembr. 2019;1861:236&#x2013;244. doi: 10.1016/j.bbamem.2018.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2018.07.009</ArticleId><ArticleId IdType="pubmed">30040926</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikhonova L.A., Kaminsky Y.G., Reddy V.P., Li Y., Solomadin I.N., Kosenko E.A., Aliev G. Impact of Amyloid &#x3b2;25-35 on Membrane Stability, Energy Metabolism, and Antioxidant Enzymes in Erythrocytes. Am. J. Alzheimer&#x2019;s Dis. Other Dement. 2014;29:685&#x2013;695. doi: 10.1177/1533317514534757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317514534757</ArticleId><ArticleId IdType="pubmed">24838531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S.-S., Jo S.A. Mechanisms of Amyloid-&#x3b2; Peptide Clearance: Potential Therapeutic Targets for Alzheimer&#x2019;s Disease. Biomol. Ther. 2012;20:245&#x2013;255. doi: 10.4062/biomolther.2012.20.3.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2012.20.3.245</ArticleId><ArticleId IdType="pmc">PMC3794520</ArticleId><ArticleId IdType="pubmed">24130920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosenko E.A., Tikhonova L.A., Montoliu C., Barreto G.E., Aliev G., Kaminsky Y.G., Kosenko E.A., Tikhonova L.A., Montoliu C., Barreto G.E., et al. Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer&#x2019;s Disease. Front. Neurosci. 2018;11:728. doi: 10.3389/fnins.2017.00728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00728</ArticleId><ArticleId IdType="pmc">PMC5760569</ArticleId><ArticleId IdType="pubmed">29354027</ArticleId></ArticleIdList></Reference><Reference><Citation>Casoli T., Di Stefano G., Giorgetti B., Grossi Y., Balietti M., Fattoretti P., Bertoni-Freddari C. Release of beta-amyloid from high-density platelets: Implications for Alzheimer&#x2019;s disease pathology. Ann. N. Y. Acad. Sci. 2007;1096:170&#x2013;178. doi: 10.1196/annals.1397.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1397.082</ArticleId><ArticleId IdType="pubmed">17405928</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C.C. Stimulated release of the beta-amyloid protein of Alzheimer&#x2019;s disease by normal human platelets. Neurosci. Lett. 1997;235:157&#x2013;159. doi: 10.1016/S0304-3940(97)00738-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(97)00738-6</ArticleId><ArticleId IdType="pubmed">9406893</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M., Vigo-Pelfrey C., Teplow D.B., Miller C., Schenk D., Johnston J., Winblad B., Venizelos N., Lannfelt L., Selkoe D.J. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl. Acad. Sci. USA. 1994;91:11993&#x2013;11997. doi: 10.1073/pnas.91.25.11993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.25.11993</ArticleId><ArticleId IdType="pmc">PMC45362</ArticleId><ArticleId IdType="pubmed">7991571</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonian N.A., Hyman B.T. Functional Alterations in Alzheimer&#x2019;s Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation. J. Neuropathol. Exp. Neurol. 1994;53:508&#x2013;512. doi: 10.1097/00005072-199409000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199409000-00010</ArticleId><ArticleId IdType="pubmed">8083692</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F., Poljak A., Valenzuela M., Mayeux R., Smythe G.A., Sachdev P.S. Meta-analysis of plasma amyloid-&#x3b2; levels in Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. JAD. 2011;26:365&#x2013;375. doi: 10.3233/JAD-2011-101977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101977</ArticleId><ArticleId IdType="pmc">PMC5660871</ArticleId><ArticleId IdType="pubmed">21709378</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong R.A. Classic beta-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer&#x2019;s disease. Curr. Neurovasc. Res. 2006;3:289&#x2013;294. doi: 10.2174/156720206778792948.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720206778792948</ArticleId><ArticleId IdType="pubmed">17109624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosenko E.A., Tikhonova L., Li Y., Poghosyan A.C., Benberin V.V., Kaminsky Y.G., Aliev G. Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia&#x2014;Potential Probing for Markers. In: Laher I., editor. Systems Biology of Free Radicals and Antioxidants. Springer; Berlin/Heidelberg, Germany: 2014. pp. 2289&#x2013;2304.</Citation></Reference><Reference><Citation>Al-Abdi S.Y. Decreased Glutathione S-transferase Level and Neonatal Hyperbilirubinemia Associated with Glucose-6-phosphate Dehydrogenase Deficiency: A Perspective Review. Am. J. Perinatol. 2017;34:305&#x2013;314. doi: 10.1055/s-0036-1585465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1585465</ArticleId><ArticleId IdType="pubmed">27464020</ArticleId></ArticleIdList></Reference><Reference><Citation>Khansari N., Whitten H., Chou Y., Fudenberg H.H. Immunological dysfunction in Alzheimer&#x2019;s disease. J. Neuroimmunol. 1984;7:279&#x2013;285. doi: 10.1016/S0165-5728(84)80027-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(84)80027-2</ArticleId><ArticleId IdType="pubmed">3871791</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K., Kueider-Paisley A., Ahmad S., Mahmoudiandehkordi S., Arnold M., Risacher S.L., Louie G., Blach C., Baillie R., Han X., et al. Association of Altered Liver Enzymes with Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Netw. Open. 2019;2:e197978. doi: 10.1001/jamanetworkopen.2019.7978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.7978</ArticleId><ArticleId IdType="pmc">PMC6669786</ArticleId><ArticleId IdType="pubmed">31365104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Dom&#xed;nguez R., Garc&#xed;a-Barrera T., Vitorica J., G&#xf3;mez-Ariza J.L. Metabolomic investigation of systemic manifestations associated with Alzheimer&#x2019;s disease in the APP/PS1 transgenic mouse model. Mol. Biosyst. 2015;11:2429&#x2013;2440. doi: 10.1039/C4MB00747F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4MB00747F</ArticleId><ArticleId IdType="pubmed">26131452</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Velpen V., Teav T., Gallart-Ayala H., Mehl F., Konz I., Clark C., Oikonomidi A., Peyratout G., Henry H., Delorenzi M., et al. Systemic and central nervous system metabolic alterations in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 2019;11:93. doi: 10.1186/s13195-019-0551-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0551-7</ArticleId><ArticleId IdType="pmc">PMC6883620</ArticleId><ArticleId IdType="pubmed">31779690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ore&#x161;i&#x10d; M., Hyotylainen T., Herukka S.-K., Sysiaho M., Mattila I., Sepp&#xe4;nan-Laakso T., Julkunen V., Gopalacharyulu P.V., Hallikainen M., Koikkalainen J., et al. Metabolome in progression to Alzheimer&#x2019;s disease. Transl. Psychiatry. 2011;1:e57. doi: 10.1038/tp.2011.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2011.55</ArticleId><ArticleId IdType="pmc">PMC3309497</ArticleId><ArticleId IdType="pubmed">22832349</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke C.E. Parkinson&#x2019;s disease. BMJ. 2007;335:441&#x2013;445. doi: 10.1136/bmj.39289.437454.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39289.437454.AD</ArticleId><ArticleId IdType="pmc">PMC1962892</ArticleId><ArticleId IdType="pubmed">17762036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey E.R., Bloem B.R. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75:9&#x2013;10. doi: 10.1001/jamaneurol.2017.3299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3299</ArticleId><ArticleId IdType="pubmed">29131880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Schmiel L., Zhou M., Cintina I., Spencer D., Hogan P. Economic Burden and Future Impact of Parkinson&#x2019;s Disease. The Lewin Group, Inc.; Falls Church, VA, USA: 2019.</Citation></Reference><Reference><Citation>Borghammer P., Chakravarty M., Jonsdottir K.Y., Sato N., Matsuda H., Ito K., Arahata Y., Kato T., Gjedde A. Cortical hypometabolism and hypoperfusion in Parkinson&#x2019;s disease is extensive: Probably even at early disease stages. Brain Struct. Funct. 2010;214:303&#x2013;317. doi: 10.1007/s00429-010-0246-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-010-0246-0</ArticleId><ArticleId IdType="pubmed">20361208</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P., Ahmed I., Fan Z., Hinz R., Gelosa G., Chaudhuri K.R., Walker Z., Turkheimer F.E., Brooks D.J. Microglia, amyloid, and glucose metabolism in Parkinson&#x2019;s disease with and without dementia. Neuropsychopharmacology. 2013;38:938&#x2013;949. doi: 10.1038/npp.2012.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2012.255</ArticleId><ArticleId IdType="pmc">PMC3629382</ArticleId><ArticleId IdType="pubmed">23303049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.-Q., Tian Q., Li D., He S.-Q., Hu M., Liu S.-Y., Zou W., Chen Y.-J., Zhang P., Tang X.-Q. Leptin mediates protection of hydrogen sulfide against 6-hydroxydopamine-induced Parkinson&#x2019;s disease: Involving enhancement in Warburg effect. Neurochem. Int. 2020;135:104692. doi: 10.1016/j.neuint.2020.104692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2020.104692</ArticleId><ArticleId IdType="pubmed">32032636</ArticleId></ArticleIdList></Reference><Reference><Citation>Flinn L.J., Keatinge M., Bretaud S., Mortiboys H., Matsui H., De Felice E., Woodroof H.I., Brown L., McTighe A., Soellner R., et al. TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Ann. Neurol. 2013;74:837&#x2013;847. doi: 10.1002/ana.23999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23999</ArticleId><ArticleId IdType="pmc">PMC4154126</ArticleId><ArticleId IdType="pubmed">24027110</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez K.L.R., Simpson J., Watson L.C., Mortiboys H., Hautbergue G.M., Bandmann O., Highley J.R. TIGAR inclusion pathology is specific for Lewy body diseases. Brain Res. 2019;1706:218&#x2013;223. doi: 10.1016/j.brainres.2018.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.09.032</ArticleId><ArticleId IdType="pubmed">30267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese C., Pay&#xe1;n-G&#xf3;mez C., Galvani M., Gonz&#xe1;lez N.M., Tresini M., Abdellah S.N., Van Roon-Mom W.M.C., Figini S., Marinus J., Van Hilten J.J., et al. Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson&#x2019;s disease. Mov. Disord. 2019;34:1192&#x2013;1202. doi: 10.1002/mds.27723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27723</ArticleId><ArticleId IdType="pmc">PMC6771759</ArticleId><ArticleId IdType="pubmed">31136028</ArticleId></ArticleIdList></Reference><Reference><Citation>Deus C.M., Pereira S.P., Cunha-Oliveira T., Pereira F.B., Raimundo N., Oliveira P.J. Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson&#x2019;s disease patients uncovers metabolic and mitochondrial bioenergetic defects. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165615. doi: 10.1016/j.bbadis.2019.165615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2019.165615</ArticleId><ArticleId IdType="pubmed">31759069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortiboys H., Thomas K.J., Koopman W.J., Klaffke S., Abou-Sleiman P., Cookson M.R., Bandmann O. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 2008;64:555&#x2013;565. doi: 10.1002/ana.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21492</ArticleId><ArticleId IdType="pmc">PMC2613566</ArticleId><ArticleId IdType="pubmed">19067348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanellati M.C., Monti V., Barzaghi C., Reale C., Nardocci N., Albanese A., Valente E.M., Ghezzi D., Garavaglia B. Mitochondrial dysfunction in Parkinson disease: Evidence in mutant PARK2 fibroblasts. Front. Genet. 2015;6:78. doi: 10.3389/fgene.2015.00078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2015.00078</ArticleId><ArticleId IdType="pmc">PMC4356157</ArticleId><ArticleId IdType="pubmed">25815004</ArticleId></ArticleIdList></Reference><Reference><Citation>Requejo-Aguilar R., Lopez-Fabuel I., Fernandez E., Martins L.M., Almeida A., Bola&#xf1;os J.P. PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. Nat. Commun. 2014;5:4514. doi: 10.1038/ncomms5514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5514</ArticleId><ArticleId IdType="pubmed">25058378</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Investig. 2013;123:3664&#x2013;3671. doi: 10.1172/JCI67230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI67230</ArticleId><ArticleId IdType="pmc">PMC3754249</ArticleId><ArticleId IdType="pubmed">23999440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosi G., Ghezzi C., Sepe S., Milanese C., Payan-Gomez C., Bombardieri C.R., Armentero M.-T., Zangaglia R., Pacchetti C., Mastroberardino P.G., et al. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson&#x2019;s disease. Biochim. Biophys. Acta. 2014;1842:1385&#x2013;1394. doi: 10.1016/j.bbadis.2014.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.05.008</ArticleId><ArticleId IdType="pubmed">24854107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z., Gandhi S., Burchell V.S., Plun-Favreau H., Wood N.W., Abramov A.Y. Cell metabolism affects selective vulnerability in PINK1-associated Parkinson&#x2019;s disease. Pt 24J. Cell Sci. 2011;124:4194&#x2013;4202. doi: 10.1242/jcs.088260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.088260</ArticleId><ArticleId IdType="pmc">PMC3258104</ArticleId><ArticleId IdType="pubmed">22223879</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson G.L., Dinsdale D., Macfarlane M., Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene. 2012;31:4996&#x2013;5006. doi: 10.1038/onc.2012.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.13</ArticleId><ArticleId IdType="pubmed">22310286</ArticleId></ArticleIdList></Reference><Reference><Citation>Marion M.-H., Qurashi M., Marshall G., Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson&#x2019;s disease? J. Neurol. 2008;255:192&#x2013;196. doi: 10.1007/s00415-008-0629-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-008-0629-9</ArticleId><ArticleId IdType="pubmed">18217187</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A.M., Depp C., Ryan B.J., Johnston G.I., Alegre-Abarrategui J., Evetts S., Rolinski M., Baig F., Ruffmann C., Simon A.K., et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson&#x2019;s blood cells. Mov. Disord. 2018;33:1580&#x2013;1590. doi: 10.1002/mds.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.104</ArticleId><ArticleId IdType="pmc">PMC6221131</ArticleId><ArticleId IdType="pubmed">30294923</ArticleId></ArticleIdList></Reference><Reference><Citation>Supandi F., van Beek J. Computational prediction of changes in brain metabolic fluxes during Parkinson&#x2019;s disease from mRNA expression. PLoS ONE. 2018;13:e0203687. doi: 10.1371/journal.pone.0203687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203687</ArticleId><ArticleId IdType="pmc">PMC6135490</ArticleId><ArticleId IdType="pubmed">30208076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri A.D., Kabaria S., Choi D.C., Mouradian M.M., Junn E. MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death. J. Biol. Chem. 2015;290:12425&#x2013;12434. doi: 10.1074/jbc.M114.625962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.625962</ArticleId><ArticleId IdType="pmc">PMC4424371</ArticleId><ArticleId IdType="pubmed">25814668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gim&#xe9;nez-Cassina A., Lim F., Cerrato T., Palomo G.M., D&#xed;az-Nido J. Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. J. Biol. Chem. 2009;284:3001&#x2013;3011. doi: 10.1074/jbc.M808698200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808698200</ArticleId><ArticleId IdType="pubmed">19033437</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona J.C., Gimenez-Cassina A., Lim F., D&#xed;az-Nido J. Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson&#x2019;s disease. J. Neurosci. Res. 2010;88:1943&#x2013;1950. doi: 10.1002/jnr.22357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22357</ArticleId><ArticleId IdType="pubmed">20143419</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong C.T., Chau K.Y., Schapira A.H. Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Sci. Rep. 2016;6:25344. doi: 10.1038/srep25344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25344</ArticleId><ArticleId IdType="pmc">PMC4857109</ArticleId><ArticleId IdType="pubmed">27145922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R., Zhang Y., Simmering J.E., Schultz J.L., Li Y., Fernandez-Carasa I., Consiglio A., Raya A., Polgreen P.M., Narayanan N.S., et al. Enhancing glycolysis attenuates Parkinson&#x2019;s disease progression in models and clinical databases. J. Clin. Investig. 2019;129:4539&#x2013;4549. doi: 10.1172/JCI129987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI129987</ArticleId><ArticleId IdType="pmc">PMC6763248</ArticleId><ArticleId IdType="pubmed">31524631</ArticleId></ArticleIdList></Reference><Reference><Citation>Foltynie T. Glycolysis as a therapeutic target for Parkinson&#x2019;s disease. Lancet Neurol. 2019;18:1072&#x2013;1074. doi: 10.1016/S1474-4422(19)30404-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30404-1</ArticleId><ArticleId IdType="pubmed">31628009</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott C.J., Shaw P.J. Diagnosis and management of motor neurone disease. BMJ. 2008;336:658&#x2013;662. doi: 10.1136/bmj.39493.511759.BE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39493.511759.BE</ArticleId><ArticleId IdType="pmc">PMC2270983</ArticleId><ArticleId IdType="pubmed">18356234</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Mazzini L., Cantello R., Mora G., Moglia C., Corrado L., D&#x2019;Alfonso S., Majounie E., Renton A., et al. Extensive genetics of ALS: A population-based study in Italy. Neurology. 2012;79:1983&#x2013;1989. doi: 10.1212/WNL.0b013e3182735d36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182735d36</ArticleId><ArticleId IdType="pmc">PMC3484987</ArticleId><ArticleId IdType="pubmed">23100398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V., ALS/Riluzole Study Group A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera T.W., Borges K. Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments. Front. Neurosci. 2016;10:611. doi: 10.3389/fnins.2016.00611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00611</ArticleId><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., De Bock K., Van Den Bosch L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Floare M.L., Allen S.P. Why TDP-43? Why Not? Mechanisms of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis. Neurosci. Insights. 2020;15:2633105520957302. doi: 10.1177/2633105520957302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2633105520957302</ArticleId><ArticleId IdType="pmc">PMC7503004</ArticleId><ArticleId IdType="pubmed">32995749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolome F., Wu H.-C., Burchell V.S., Preza E., Wray S., Mahoney C.J., Fox N.C., Calvo A., Canosa A., Moglia C., et al. Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron. 2013;78:57&#x2013;64. doi: 10.1016/j.neuron.2013.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.028</ArticleId><ArticleId IdType="pmc">PMC3843114</ArticleId><ArticleId IdType="pubmed">23498975</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Duffy L.M., Shaw C.E., Grierson A.J. Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol. Aging. 2015;36:2893&#x2013;2903. doi: 10.1016/j.neurobiolaging.2015.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.07.013</ArticleId><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Rajan S., Duffy L., Mortiboys H., Higginbottom A., Grierson A.J., Shaw P.J. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiol. Aging. 2014;35:1499&#x2013;1509. doi: 10.1016/j.neurobiolaging.2013.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.025</ArticleId><ArticleId IdType="pubmed">24439480</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R., Allen S.P., Goodall E.F., Kramer S., Ponger L.-L., Heath P.R., Milo M., Hollinger H.C., Walsh T., Highley J.R., et al. Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. Neuropathol. Appl. Neurobiol. 2015;41:201&#x2013;226. doi: 10.1111/nan.12147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12147</ArticleId><ArticleId IdType="pmc">PMC4329387</ArticleId><ArticleId IdType="pubmed">24750211</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena G.N., Rizzardini M., Cimini S., Siskos A.P., Bendotti C., Cantoni L., Keun H.C. Metabolomic Analysis Reveals Increased Aerobic Glycolysis and Amino Acid Deficit in a Cellular Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2016;53:2222&#x2013;2240. doi: 10.1007/s12035-015-9165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9165-7</ArticleId><ArticleId IdType="pmc">PMC4823370</ArticleId><ArticleId IdType="pubmed">25963727</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., Lorenzini I., Barrameda D., O&#x2019;Conner A.G., Barrows J.M., Starr A., Kovalik T., Rabichow B.E., Lehmkuhl E.M., Shreiner D.D., et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019;8:e45114. doi: 10.7554/eLife.45114.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45114</ArticleId><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Kirk S.E., Tefera T.W., Xie T.Y., Tracey T.J., Kelk D., Wimberger E., Garton F.C., Roberts L., Chapman S.E., et al. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis (ALS) bioRxiv. 2020 doi: 10.1101/2020.04.02.021238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.02.021238</ArticleId><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk S.E., Tracey T.J., Steyn F.J., Ngo S.T. Biomarkers of Metabolism in Amyotrophic Lateral Sclerosis. Front. Neurol. 2019;10:191. doi: 10.3389/fneur.2019.00191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00191</ArticleId><ArticleId IdType="pmc">PMC6431787</ArticleId><ArticleId IdType="pubmed">30936848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew S., Atassi N. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis. Front. Neurol. 2019;10:135. doi: 10.3389/fneur.2019.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6405430</ArticleId><ArticleId IdType="pubmed">30881332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauckneht M., Lai R., Miceli A., Schenone D., Cossu V., Donegani M.I., Raffa S., Borra A., Marra S., Campi C., et al. Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: A computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Res. 2020;10:23. doi: 10.1186/s13550-020-0607-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13550-020-0607-5</ArticleId><ArticleId IdType="pmc">PMC7085992</ArticleId><ArticleId IdType="pubmed">32201914</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Woof R., Francis L., Gatto N., Shaw A.C., Myszczynska M., Hemingway J., Coldicott I., Willcock A., et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142:3771&#x2013;3790. doi: 10.1093/brain/awz302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId><ArticleId IdType="pmc">PMC6906594</ArticleId><ArticleId IdType="pubmed">31647549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R.C., Chami A.A., De Assis D.R., Vourc&#x2019;H P., Andres C.R., Corcia P., Lanznaster D., Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L., Schlagowski A., Ngo S.T., Vernay A., Dirrig-Grosch S., Henriques A., Boutillier A., Zoll J., Echaniz-Laguna A., Loeffler J.-P., et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol. Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Fidler J.A., Tamsett T.J., Bao C., Searles M., Taksir T.V., Misra K., Sidman R.L., Cheng S.H., et al. Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc. Natl. Acad. Sci. USA. 2013;110:10812&#x2013;10817. doi: 10.1073/pnas.1308421110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1308421110</ArticleId><ArticleId IdType="pmc">PMC3696768</ArticleId><ArticleId IdType="pubmed">23754387</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C., Cossu V., Bonifacino T., Bauckneht M., Torazza C., Bruno S., Castellani P., Ravera S., Milanese M., Venturi C., et al. Mechanisms underlying the predictive power of high skeletal muscle uptake of FDG in amyotrophic lateral sclerosis. EJNMMI Res. 2020;10:76. doi: 10.1186/s13550-020-00666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13550-020-00666-6</ArticleId><ArticleId IdType="pmc">PMC7340686</ArticleId><ArticleId IdType="pubmed">32638178</ArticleId></ArticleIdList></Reference><Reference><Citation>Golko-Perez S., Amit T., Youdim M.B.H., Weinreb O. Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS Mice. J. Mol. Neurosci. 2016;59:504&#x2013;510. doi: 10.1007/s12031-016-0763-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-016-0763-2</ArticleId><ArticleId IdType="pubmed">27173029</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Lee J.D., Woodruff T.M., Henderson R.D. The Peripheral Immune System and Amyotrophic Lateral Sclerosis. Front. Neurol. 2020;11:279. doi: 10.3389/fneur.2020.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00279</ArticleId><ArticleId IdType="pmc">PMC7186478</ArticleId><ArticleId IdType="pubmed">32373052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostalski H., Leskel&#xe4; S., Huber N., Katisko K., Cajanus A., Solje E., Marttinen M., Natunen T., Remes A.M., Hiltunen M., et al. Astrocytes and Microglia as Potential Contributors to the Pathogenesis of C9orf72 Repeat Expansion-Associated FTLD and ALS. Front. Neurosci. 2019;13:486. doi: 10.3389/fnins.2019.00486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00486</ArticleId><ArticleId IdType="pmc">PMC6529740</ArticleId><ArticleId IdType="pubmed">31156371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia R., Shepheard S., Jin J., Hu F., Zhao X., Xue L., Xiang L., Qi H., Qu Q., Guo F., et al. Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort. Sci. Rep. 2017;7:5127. doi: 10.1038/s41598-017-05430-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-05430-w</ArticleId><ArticleId IdType="pmc">PMC5506052</ArticleId><ArticleId IdType="pubmed">28698670</ArticleId></ArticleIdList></Reference><Reference><Citation>Matusica D., Alfonsi F., Turner B.J., Butler T.J., Shepheard S.R., Rogers M.L., Skeldal S., Underwood C.K., Mangelsdorf M., Coulson E.J. Inhibition of motor neuron death in vitro and in vivo by a p75 neurotrophin receptor intracellular domain fragment. J. Cell Sci. 2016;129:517&#x2013;530. doi: 10.1242/jcs.173864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.173864</ArticleId><ArticleId IdType="pubmed">26503157</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Chataway T., Schultz D.W., Rush R.A., Rogers M.-L. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE. 2014;9:e87398. doi: 10.1371/journal.pone.0087398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087398</ArticleId><ArticleId IdType="pmc">PMC3903651</ArticleId><ArticleId IdType="pubmed">24475283</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Wuu J., Cardoso M., Wiklendt L., Dinning P.G., Chataway T., Schultz D., Benatar M., Rogers M.L. Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2013;1143. doi: 10.1212/WNL.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>DiStefano P.S., Johnson E.M., Jr. Identification of a truncated form of the nerve growth factor receptor. Proc. Natl. Acad. Sci. USA. 1988;85:270&#x2013;274. doi: 10.1073/pnas.85.1.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.1.270</ArticleId><ArticleId IdType="pmc">PMC279526</ArticleId><ArticleId IdType="pubmed">2829174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O., Bordoni M., Drufuca L., Diamanti L., Sproviero D., Trotti R., Bernuzzi S., La Salvia S., Gagliardi S., Ceroni M., et al. Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms. Dis. Model. Mech. 2018;11:dmm031625. doi: 10.1242/dmm.031625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.031625</ArticleId><ArticleId IdType="pmc">PMC5897724</ArticleId><ArticleId IdType="pubmed">29419416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>